The patent covers Delpor’s PROZORTM technology which enables the sustained release of antipsychotics and other molecules from a matchstick-size implant device.
Delpor has several products in development, including a 6-month formulation of risperidone, and a 3-month formulation of olanzapine for schizophrenia maintenance treatment.
SAN FRANCISCO, CA, March 7, 2017 –Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that the United States Patent and Trademark Office issued on February 7, 2017 U.S. Patent No. 9,561,352 covering Delpor’s implantable device for the long-term delivery of therapeutic agents. The device uses Delpor’s proprietary PROZORTM technology for the sustained release of drugs for several months after subcutaneous implantation. Delpor has several product candidates in development, including a 6-month formulation of risperidone and a 3-month formulation of olanzapine, that are covered by the newly issued patent.
Numerous therapeutic agents including risperidone, olanzapine, asenapine, and other CNS molecules can benefit from long-term sustained delivery. The benefits of such delivery include improved medication adherence, as well as a “smooth” pharmacokinetic profile resulting in enhanced safety and tolerability. Most CNS drugs, as well as other important classes, exhibit poor water solubility at neutral pH, creating challenges to the development of implantable sustained delivery systems which rely on passive diffusion as the primary drug release mechanism. Delpor’s proprietary PROZOR technology enables the release of antipsychotics and other agents for several months through passive diffusion, based on a unique formulation. Furthermore, Delpor’s drug delivery implant device, offers full reversibility if treatment discontinuation is needed due to adverse events.
“The issuance of this patent recognizes the novelty of the underlying technology and marks the beginning of a new family of patents for Delpor, making it a key component of our intellectual property portfolio” said Tassos Nicolaou, President and CEO of Delpor. “The PROZOR technology overcomes the solubility challenges faced by most CNS drugs, and creates the potential for several sustained release long acting therapeutic products, lasting as long as one year. Our lead risperidone program is currently utilizing this unique approach to create a 6-month formulation of the drug which should result in superior clinical outcomes through improved medication adherence.”
Tassos Nicolaou continued: “If treatment discontinuation is needed due to adverse events, the implant can be easily removed by a healthcare professional, and drug plasma levels drop to zero within a day. Our goal is to further expand the use of this innovative platform for the delivery of other agents including the antipsychotics olanzapine and asenapine
About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. Delpor’s device can deliver small & large molecules over several months while maintaining zero-order release pharmacokinetics. The company’s lead products include 3-6 month formulations of Risperidone and Exenatide. Additional information about the company can be found at www.delpor.com.
Delpor’s PROZOR technology enables the sustained release of certain insoluble drugs (including most antipsychotics) from a non-mechanical (passive) implantable drug delivery device based on a unique formulation. A typical formulation is a mixture of the drug and a group of excipients designed to regulate the pH over time. The formulation is in the form of an aqueous suspension held within a small cylindrical reservoir fitted at each end with conventional membranes.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
Tassos Nicolaou, President and CEO